Document is current
Any future updates will be listed below
-
Authors
Bektash, Fatma
Ouda, Heba Hossam
Hassan, Yasmine
El-Sayed, Asmaa
Shash, Emad
-
Funding
Funding for this research was provided by:
Cairo University
- License Information
-
More Information
Article History
Received: 12 August 2024
Accepted: 7 May 2025
First Online: 19 May 2025
Declarations
:
: Ethical approval was not required for this study as it did not involve any experimental intervention or direct interaction with human participants. The research utilized publicly available data and literature, ensuring that no confidential or personally identifiable information was accessed or used. Additionally, the questionnaire used in part of the study is a standard of care instrument at our institution, further supporting the exemption from ethical approval.
: E.S.: •Advisory board meetings/Consultancy/Speaker's bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Clinart MENA, Genomics Genetics, GSK, Hikma, EVA Pharma, Janssen, Lilly, MSD, Mundipharma, Newbridge Pharmaceutical, Novartis, Pfizer, Pierre Fabre, Roche, and Sandoz. •Travel grants: Boehringer Ingelheim, Hikma, Janssen, Lilly, MSD, Mundipharma, Novartis, Pfizer, and Roche. •Clinical trials Involvement: AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, and Roche. F.B.: •Travel Grants: Pfizer. Y.H.: Y. H. is Director, Oncology Patient Affairs at AstraZeneca. The remaining authors have no relevant financial or non-financial interests to disclose.
